81 related articles for article (PubMed ID: 31576687)
1. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Konner JA; Grabon DM; Gerst SR; Iasonos A; Thaler H; Pezzulli SD; Sabbatini PJ; Bell-McGuinn KM; Tew WP; Hensley ML; Spriggs DR; Aghajanian CA
J Clin Oncol; 2011 Dec; 29(35):4662-8. PubMed ID: 22067389
[TBL] [Abstract][Full Text] [Related]
3. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.
Nasioudis D; Wang X; Dhillon G; Latif N; Ko EM; Giuntoli RL; Gershenson D; Fader A; Carey M; Simpkins F
Int J Gynecol Cancer; 2023 Dec; 33(12):1906-1912. PubMed ID: 37879909
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD005340. PubMed ID: 26755441
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
[TBL] [Abstract][Full Text] [Related]
6. Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
Lietz AP; Weaver DT; Melamed A; Rauh-Hain JA; Wright JD; Wright AA; Knudsen AB; Pandharipande PV
PLoS One; 2019; 14(9):e0222828. PubMed ID: 31539415
[TBL] [Abstract][Full Text] [Related]
7. Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
van Stein RM; Engbersen MP; Stolk T; Lopez-Yurda M; Lahaye MJ; Beets-Tan RGH; Lok CAR; Sonke GS; Van Driel WJ
Gynecol Oncol; 2022 Nov; 167(2):269-276. PubMed ID: 36088169
[TBL] [Abstract][Full Text] [Related]
8. Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications.
de Jong D; Thangavelu A; Broadhead T; Chen I; Burke D; Hutson R; Johnson R; Kaufmann A; Lodge P; Nugent D; Quyn A; Theophilou G; Laios A
J Ovarian Res; 2023 Nov; 16(1):214. PubMed ID: 37951927
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor type on response to adjuvant platinum-based chemotherapy and prognosis in patients with stage II-IV epithelial ovarian carcinoma.
Aktemur G; Kilic C; Kilic F; Ünsal M; Kimyon Comert G; Turan T
Ginekol Pol; 2024; 95(2):99-107. PubMed ID: 37668391
[TBL] [Abstract][Full Text] [Related]
10. Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
Kitsos-Kalyvianakis K; Pitsikakis K; Mamalis ME; Kalampokis E; Tan YS; Thangavelu A; Broadhead T; Nugent D; Dejong D; Laios A
Anticancer Res; 2024 Jun; 44(6):2645-2652. PubMed ID: 38821579
[TBL] [Abstract][Full Text] [Related]
11. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract][Full Text] [Related]
12. The use of intraperitoneal chemotherapy for advanced ovarian cancer - The experience of a tertiary referral centre.
Foster L; Girgis C; Kirby A; Harnett P; Brand A
Aust N Z J Obstet Gynaecol; 2023 Nov; ():. PubMed ID: 37994114
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.
Zhao M; Gao Y; Yang J; He H; Su M; Wan S; Feng X; Wang H; Cai H
Eur J Med Res; 2024 Mar; 29(1):179. PubMed ID: 38494480
[TBL] [Abstract][Full Text] [Related]
14. Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.
Harsh KK; Jakhar SL; Maheshwari G; Nirban R; Kumari P; Beniwal SK; Sharma N; Kumar HS
Indian J Cancer; 2023; 60(2):167-172. PubMed ID: 37530237
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients.
Cunnea P; Gorgy T; Petkos K; Gowers SAN; Lu H; Morera C; Wu W; Lawton P; Nixon K; Leong CL; Sorbi F; Domenici L; Paterson A; Curry E; Gabra H; Boutelle MG; Drakakis EM; Fotopoulou C
Sci Rep; 2018 Oct; 8(1):14695. PubMed ID: 30279418
[TBL] [Abstract][Full Text] [Related]
16. Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia.
Shah R; Polen-De C; McGree M; Fought A; Kumar A
Curr Oncol; 2023 Oct; 30(11):9501-9513. PubMed ID: 37999108
[TBL] [Abstract][Full Text] [Related]
17. Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
Bui A; Gehrig PA; Ghamande S; Rungruang BJ; Chan JK; Mysona DP
Gynecol Oncol; 2022 Nov; 167(2):205-212. PubMed ID: 36055814
[TBL] [Abstract][Full Text] [Related]
18. Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer.
Faria FH; Lage APD; Rodrigues AN; Wainstein AJA
Rev Col Bras Cir; 2022; 49():e20223231. PubMed ID: 36449939
[TBL] [Abstract][Full Text] [Related]
19. Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Byrne M; Sia TY; Fong C; Khurram A; Waters M; Kemel YM; Zhou Q; Ranganathan M; Long Roche K; Chi DS; Saban S; Wu M; Varice N; Hamilton JG; Carrot-Zhang J; Abu-Rustum NR; Iasonos A; Ellenson LH; Mandelker D; Weigelt B; Brown CL; Aghajanian C; Stadler Z; Liu YL
Gynecol Oncol; 2024 Apr; 183():126-132. PubMed ID: 38493020
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Cancer in the Older Manitoban Population-Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study.
Roberts LF; Lambert P; Nachtigal MW; Altman AD; Dean E
Curr Oncol; 2024 Mar; 31(3):1348-1358. PubMed ID: 38534935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
